Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monique Celeste Tavares

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The British Journal of Radiology|January 30, 2026
MRI Response to Neoadjuvant Chemotherapy and Prognostic Implications in Breast Cancer PatientsSoraia Quaranta Damião, Eduarda Ferreira Rodrigues da Cunha, Monique Celeste Tavares, et al.
Breast Cancer Research and Treatment|August 19, 2021
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancerLuciana de Moura Leite, Marcelle Goldner Cesca, Monique Celeste Tavares, et al.
Breast Cancer Research and Treatment|March 23, 2026
Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancerLuciana de Moura Leite, Guilherme Rossato de Almeida, Monique Celeste Tavares, et al.
NPJ Breast Cancer|August 14, 2024
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancerRenata Colombo Bonadio, Isadora Martins de Sousa, Flávia Cavalcanti Balint, et al.
Breast Cancer Research and Treatment|February 3, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real studyRenata Colombo Bonadio, Monique Celeste Tavares, Flávia Cavalcanti Balint, et al.
Breast (Edinburgh, Scotland)|April 16, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Isabella Gonçalves Gutierres, Monique Celeste Tavares, et al.
Breast Cancer Research and Treatment|March 18, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Renata Colombo Bonadio, Agustina Ipiña, et al.
NPJ Breast Cancer|March 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, Laura Lapuchesky, et al.
NPJ Breast Cancer|June 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohortMonique Celeste Tavares, Flávia C Balint, Romualdo Barroso-Sousa, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The British Journal of Radiology|January 30, 2026
MRI Response to Neoadjuvant Chemotherapy and Prognostic Implications in Breast Cancer PatientsSoraia Quaranta Damião, Eduarda Ferreira Rodrigues da Cunha, Monique Celeste Tavares, et al.
Breast Cancer Research and Treatment|August 19, 2021
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancerLuciana de Moura Leite, Marcelle Goldner Cesca, Monique Celeste Tavares, et al.
Breast Cancer Research and Treatment|March 23, 2026
Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancerLuciana de Moura Leite, Guilherme Rossato de Almeida, Monique Celeste Tavares, et al.
NPJ Breast Cancer|August 14, 2024
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancerRenata Colombo Bonadio, Isadora Martins de Sousa, Flávia Cavalcanti Balint, et al.
Breast Cancer Research and Treatment|February 3, 2025
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real studyRenata Colombo Bonadio, Monique Celeste Tavares, Flávia Cavalcanti Balint, et al.
Breast (Edinburgh, Scotland)|April 16, 2025
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Isabella Gonçalves Gutierres, Monique Celeste Tavares, et al.
Breast Cancer Research and Treatment|March 18, 2026
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 studyMatheus de Oliveira Andrade, Renata Colombo Bonadio, Agustina Ipiña, et al.
NPJ Breast Cancer|March 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, Laura Lapuchesky, et al.
NPJ Breast Cancer|June 2, 2026
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohortMonique Celeste Tavares, Flávia C Balint, Romualdo Barroso-Sousa, et al.
Pageof 1